GlassScriptPhysician profile
Adekunle S Adegbite
NPI 1407494735
$8,907.20
in general payments reported to CMS, 2019-2025
21 companies · $3,448 in 2025
The $3,448 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $308 · 2022: $924 · 2023: $2,179 · 2024: $2,048 · 2025: $3,448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,600 · Education: $75.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,600.09 |
| Education | $75.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,349.14 | 2022-2025 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $1,034.34 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $994.51 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $935.96 | 2021-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $884.04 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $878.76 | 2022-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Alkermes, INC. | $869.15 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Lundbeck LLC | $554.56 | 2023-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $309.39 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $187.77 | 2021-2022 | |
| Indivior INC. | $182.22 | 2023-2024 | Perseris |
| Vanda Pharmaceuticals INC. | $153.66 | 2021-2025 | Fanapt, Hetlioz |
| Collegium Pharmaceutical, INC. | $146.91 | 2025 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $138.76 | 2021-2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $84.79 | 2022-2024 | Trintellix |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $58.60 | 2023-2024 | Jornay Pm |
| Axsome Therapeutics, INC. | $49.84 | 2023-2024 | Auvelity |
| Corium, LLC | $31.05 | 2023 | Azstarys |
| Janssen Scientific Affairs, LLC | $28.65 | 2023 | Spravato |
| Merck Sharp & Dohme LLC | $18.78 | 2022 | |
| Almatica Pharma LLC | $16.32 | 2025 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adekunle Adegbite listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.